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 characterized  subgroups of ILD (3–5), 
and among these, variants in the 
ATP-binding cassette sub-family A  
member 3 (ABCA3) are the most  
frequent cause (6–8).
The carrier frequency of heterozygous 
ABCA3 variants in the population pre-
dicts disease prevalence of 1 in ~3,100 
of European descent and a total of ~750 
homozygous newborns annually in the 
United States (9). This  incidence is in the 
range of that for cystic fibrosis (about 1 in 
2,500 for  European descent infants) (10). 
 However, sick patients carrying ABCA3 
variants are not as frequently identified 
as could be  expected based on these 
numbers. The main reason for this is the 
 interstitium (1). The disease spectrum 
is much broader in childhood, as many 
 diseases primarily manifest during 
 infancy (2). The surfactant dysfunction 
disorders are the best  molecularly 
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Interstitial lung diseases (ILD) 
 encompass a large number of diffuse 
parenchymal lung disorders involving 
the lung parenchyma and the alveolar 
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The ABCA3 gene encodes a lipid transporter in type II pneumocytes critical for survival and normal respiratory  function. The 
frequent ABCA3 variant R288K increases the risk for neonatal respiratory distress syndrome among term and late preterm neonates, 
but its role in children’s interstitial lung disease has not been studied in detail. In a retrospective cohort study of 228 children with 
interstitial lung disease related to the alveolar surfactant  system, the frequency of R288K was assessed and the phenotype of 
patients carrying a single R288K variant further characterized by clinical course, lung histology, computed tomography and bron-
choalveolar lavage phosphatidylcholine PC 32:0. Cell lines  stably transfected with ABCA3-R288K were analyzed for intracellular 
transcription, processing and targeting of the protein. ABCA3  function was assessed by detoxification assay of doxorubicin, and 
the induction and volume of lamellar bodies. We found nine children with interstitial lung disease carrying a heterozygous R288K 
variant, a frequency significantly higher than in the general Caucasian population. All identified patients had neonatal respiratory 
insufficiency, recovered and developed chronic interstitial lung disease with intermittent exacerbations during early childhood. In 
vitro analysis showed normal transcription, processing, and targeting of ABCA3-R288K, but impaired detoxification function and 
smaller lamellar bodies. We propose that the R288K variant can underlie interstitial lung disease in childhood due to reduced function of 
ABCA3, demonstrated by decelerated detoxification of doxorubicin, reduced PC 32:0 content and decreased lamellar body volume.
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Ethics Statement
All parents or guardians of the  children 
gave their informed consent; an older 
youth assented. The retrospective analy-
sis of the data was approved by the insti-
tutional review board (EK 026-06) of the 
University of Munich. Prospective collec-
tion and analysis of data was performed 
under (EK 257-10) and the  FP7-305653 
project chILD-EU (EK 111-13).
Genetic analysis for ABCA3, SFTPC, 
and SFTPB
Patients were investigated for vari-
ants in exons 4 to 33 of the ABCA3 gene 
(NM_001089), in exons 1 to 11 of the 
SFTPB gene (NM_000542) and in exons 1 
to 5 of the SFTPC gene (NM_003018) (22). 
Genomic DNA were amplified by PCR 
using the primers listed (Supplementary 
Table 4). Electrophoresis of sequenced 
products was performed on an Applied 
Biosystems 3130xl Genetic Analyzer.
Plasmids
pT2/HB transposon  vector was pur-
chased from Addgene (plasmid #26557). 
First, the puromycin resistance gene with 
corresponding PGK promoter elements 
was amplified from pLKO.1puro vec-
tor (purchased from Addgene, plasmid 
#8453) and cloned into the pT2/HB vector 
using EcoRI and HindIII restriction sites, 
yielding pT2/HB-puro. Second, ABCA3 
cDNA fused to a C-terminal HA-tag 
was amplified with corresponding cyto-
megalovirus (CMV) promoter elements 
from pcDNA4TO-ABCA3-HA vector 
and cloned into pT2/HB-puro using 
NheI and NotI restriction sites, yielding 
pT2/HB-puro-ABCA3-HA. The R288K 
point variant was introduced into pT2/
HB-puro-ABCA3-HA using the Q5® site- 
directed mutagenesis kit with the following 
primers: R288K-for 5′-GAGAA GGAAA 
AGAGG CTGAA GGAGT AC-3′ and 
R288K-rev 5′-CTGCA CGACA GCACG 
GGC-3′. pCMV(CAT)T7-SB100 transposase 
was ordered from Addgene (plasmid 
#34879). All resulting vector constructs 
were verified using Sanger sequencing. 
Sequence analysis and alignment was done 
using Clone  Manager Suite (Version 6.00).
content in bronchoalveolar lavage 
of infants and raised surface tension 
compared with control group (19,20). 
Molecular species patterns of phos-
phatidylcholine, that is, dipalmitoyl- 
phosphatidylcholine (PC 32:0), were 
also decreased in lavage of  affected 
children (20).
In this study we investigated the hy-
pothesis that the ABCA3 variant R288K 
may be permissive for  children’s inter-
stitial lung disease. Supportive of such 
a connection would be an increased fre-
quency of this variant in a population of 
patients affected by ILD over the general 
population, ex vivo evidence from these 
subjects for a certain functional impair-
ment related to ABCA3 and in vitro data 
from cells expressing this variant and 




Between 2003 and 2012, 377 infants 
and children were diagnosed in the 
program for rare lung diseases of the 
Kids-Lung Register as suffering from 
ILD related to the alveolar surfactant 
region on a clinical, radiological and 
sometimes histological basis (21). Of 
these patients, 228 were sequenced for 
variants in the ABCA3 gene. In 62 pa-
tients possible disease causing variants 
were identified and R288K was present 
in 11 cases. The latter patients were an-
alyzed in more detail ( Supplementary 
Tables 1, 2, 3). Two of these children 
(patients 10 and 11 in Supplementary 
Table 1) had additional damaging 
 homozygous ABCA3 variants very 
likely to cause ABCA3 insufficiency and 
determine their clinical course. These 
subjects were considered separately 
in further analysis as we intended to 
understand the role of heterozygous 
R288K alone or in association with 
nondamaging variants. As control 
cohorts for the sequence variant fre-
quencies the  Caucasian collections were 
used ( National Heart, Lung and Blood 
 Institute Exome Variant Server [EVS]).
 relatively large, and thus costly, analysis 
of the ABCA3 gene, which is  assessed 
mainly in very severe, frequently lethal 
courses of respiratory distress syn-
drome in the mature neonate (11,12). 
Additional reasons  include many 
not, or only poorly, defined ABCA3 
variants with unclear pathogenic sig-
nificance (9,13). Some  variants lead 
to rare but  well- characterized chronic 
children’s interstitial lung disease 
with a firm  histopathological pattern 
including desquamative interstitial 
pneumonitis or nonspecific interstitial 
 pneumonitis (14,15). The ABCA3 variant 
R288K (c.863G>A) has been previously 
associated with pediatric respiratory 
disease (6) and a single copy was 
three- to  four-fold enriched among the 
European-descent infants with neonatal 
 respiratory distress (9,16,17), although it 
is predicted to be benign and tolerated 
by the algorithms Polyphen and SIFT.
ABCA3 is a lipid transporter in 
 alveolar type II cells, where it localizes 
to the outer membrane of lamellar 
bodies (LBs) which store surfactant. 
 Variants in the ABCA3 gene can 
 impair the intracellular localization, 
processing and transport activity of 
the ABCA3 protein. For instance, 
ABCA3 with the variants L101P, L982P, 
L1553P, Q1591P and Ins1518fs/ter1519 
was retained in the endoplasmatic 
 reticulum, whereas N568D, G1221S and 
L1580P mutant ABCA3 proteins were 
correctly loca lized in the LB limiting 
membrane, but showed decreased 
ATP  hydrolysis activity compared 
with wild-type  protein (12). ABCA3 
activity is also linked to LB biogene-
sis. Heterozygous ABCA3+/- knockout 
mice had fewer LB in their lungs (18). 
Radiolabeled substrates, which were 




ine molecules, were lower in both LB 
and surfactant when compared with 
ABCA3+/+ mice (18). Additionally, 
inherited ABCA3 variants caused a 
decrease of total phosphatidylcholine 
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 Following gel electrophoresis, proteins 
were blotted to polyvinylidene fluoride 
membranes. After transfer, membranes 
were blocked with 5% skimmed milk in 
Tris-buffered saline with Tween (TBS-T). 
Membranes were incubated overnight 
with primary antibodies in blocking 
solution. After washing the membranes 
three times with TBS-T, HRP-conjugated 
secondary antibodies were applied 1 h 
at room temperature. Detection was per-
formed using ECL reagent.
Viability assay
Cell viability was assessed by 
 determining cleavage of 2,3-bis 
(2-methoxy-4-nitro- sulfophenyl)-2H-
tetrazolium-5-carboxyanilide in the pres-
ence of phenazine methosulfate. For XTT 
assay, cells were seeded in 96-well plates 
in RPMI medium containing 10% FCS and 
no phenol red. After different points of 
time, absorbance was measured at 490 nm 
and 650 nm using a spectrophotometer.
Cytotoxicity assay
Triplicates of A549 cells stably 
transfected with ABCA3-WT and 
ABCA3-R288K and cells transfected with 
mock control were seeded into six-well 
plates. After an incubation time of 96 h, 
cell supernatants were harvested and 
the amount of the lactate dehydrogenase 
(LDH) enzyme was quantified colori-
metrically at 490 nm using the  CytoTox 
96® Non-Radioactive  Cytotoxicity 
Assay according to the manufactur-
er’s instructions. The resulting optical 
densities were referred to numbers of 
cells counted with the Cellometer Auto 
T4 Cell Viability Counter.
Lipid analyses of Human 
Bronchoalveolar Lavages
After protein level determination, lip-
ids of bronchoalveolar  lavages (BALs) 
obtained from the  patients were ana-
lyzed by ESI-MS/MS in positive ion 
mode as described in (20).
Doxorubicin assay
For doxorubicin assay HEK293 cells 
stably expressing ABCA3 wild-type 
(90% glycerine in phosphate-buffered  
saline and 2% DABCO). Objects were 
viewed with an Olympus IX81/Fluoview 
FV1000 confocal laser scanning micro-
scope and imaged with the Olympus 
Fluoview version 4.2 software.
Real-time PCR
Total RNA was collected from cells 
grown for 48 h in six-well plates using 
the High-Pure RNA Isolation Kit accord-
ing to the manufacturer’s instructions. 
RNA concentrations were determined 
with a NanoDrop  spectrophotometer. 
One microgram of total RNA was tran-
scribed into cDNA with the Tetro cDNA 
Synthesis Kit.  Real-time PCR was carried 
out on a 7900HT Fast Real-Time PCR 
System using SYBR green and the fol-
lowing primers: ABCA3-for 5′-CATGG 
TCAGC ACCTT CTTCA-3′, ABACA3-rev 
5′-TTCTG GCTCA GAGTC ATCCA-3′, 
HPRT-for 5′-GCTGA CCTGC TGGAT 
TAC-3′ HPRT-rev 5′-TGCGA CCTTG 
ACCAT CTT. Relative changes in gene 
expression caused by ABCA3-WT  
or R288K variant were calculated using 




Cells were seeded in six-well plates 
for 48 h and then rinsed with PBS once 
and subsequently trypsinized and 
again washed with PBS. After that, cells 
were lysed with radioimmunoprecip-
itation assay (RIPA) buffer containing 
0.15 mol/L sodium chloride, 1% Triton-X 
100, 0.5% sodium deoxycholate, 0.1% 
sodium dodecylsulfate, 5 mmol/L eth-
ylene diamine tetraacetic acid (EDTA) 
and 50 mmol/L Tris pH 8. RIPA buffer 
was accomplished by complete protease 
inhibitor. The lysate was centrifuged for 
30 min at 1,000 × ɡ and 4°C. The protein 
concentration of the post-nuclear super-
natant (that is, whole-cell lysate) was 
determined with the Pierce BCA protein 
assay using bovine serum albumin as 
the protein standard. In total, 20 μg of 
cell lysates in 4× LDS buffer were loaded 
onto NuPage Mini Tris-Acetate gels. 
antibodies
The following antibodies were used: rab-
bit anti-HA, rat anti-HA, mouse anti-CD63, 
mouse anti-calnexin, chicken horse radish 
peroxidase (HRP)-conjugated anti-β-Actin, 
Alexa Fluor 488 goat anti-rabbit IgG and 
Alexa Fluor 555 goat anti-mouse IgG.
Cell Culture
Human A549 and HEK293 cells were 
purchased from the German Collection of 
Microorganisms and Cell Cultures. Both 
cell lines were maintained in RPMI 1640 
medium supplemented with 10% fetal 
calf serum (FCS) at 37°C and 5% CO2.
Ha Generation of Single Clones Stably 
Expressing aBCa3-Ha
To evaluate the effect of the R288K 
point variant in vivo, ABCA3-HA wildtype 
(WT) and mutated protein were stably 
transfected using the Sleeping Beauty 
transposon system into A549 cells and 
HEK293 cells, respectively. Therefore 
cells were seeded into six-well plates and 
cotransfected with pCMV(CAT)T7-SB100 
and pT2/HB-puro-ABCA3-HA WT or 
R288K respectively in the ratio of 2:5 using 
X-tremeGENE HP DNA transfection re-
agent. Forty-eight hours posttransfection, 
selection of stable cells was started by ad-
dition of 1 μg/mL puromycin. Single cell 
clones were obtained by transferring sin-
gle cells into the wells of a 96-well plate.
immunofluorescence Staining
Stable A549 cells grown in eight-well 
slides were washed twice with PBS and 
fixed with 4% paraformaldehyde for 20 min. 
After treating with 0.1 mol/L glycine in 
PBS, cells were permeabilized with 0.1% 
Triton X-100 for 10 min. Unspecific binding 
sites-were blocked with 3% bovine serum 
albumin and 10% FCS in PBS for 30 min. 
Labeling with primary antibodies was 
carried out for 1 h at room temperature. 
Cells were washed three times with PBS 
and stained with the appropriate Alexa 
Fluor secondary antibodies. After washing 
three times with PBS, cells were stained 
with 0.1 μg/mL DAPI for 10 min and 
washed with PBS. The cells were imme-
diately covered with mounting medium 
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children, the initial manifestation of  
lung disease was during the neonatal 
 period, only five were premature  infants 
(median gestational age 30 wks, range 
27 to 32). Six children were mechanically 
ventilated; most recovered and had 
chronic or intermittent episodes with 
respiratory symptoms during infancy 
and childhood. Those old enough to per-
form lung function tests had restrictive 
lung disease (Supplementary Table 2). 
The computed tomography pattern was 
consistent with ILD in six of the nine 
children. In two where no CT scan was 
 available, histology documented ILD. 
Six of the nine children had lung biop-
sies, always showing ILD alone or in 
combination with emphysematous areas 
(Supplementary Table 3).
no Evidence for impaired aBCa3 
transport activity in Children with 
Chronic iLD and Heterozygous  
for R288K
Initially, we excluded severe ABCA3 
deficiency as the molecular cause of the 
diseases by excluding complete ABCA3 
deficiency and demonstrating evidence 
for some ABCA3 function (Table 2). 
The subjects had regular ABCA3 his-
topathologic staining (available in four 
subjects), had normally formed lamellar 
bodies (available in three subjects) or 
had a  dipalmitoyl-phosphatidylcholine 
(PC 32:0) content in bronchoalveolar 
 lavage (in six subjects available) that 
was on  average a little higher than 
typically found in infants with ABCA3 
deficiency, but significant lower than in 
classes and phosphatidylcholine (PC) 
species were analyzed using two-way 
repeated measure ANOVAs with Sidak 
post hoc test. Results were presented as 
mean ± SEM of a minimum of three dif-
ferent experiments. P values <0.05 were 
considered to be statistically significant. 
All tests were performed using Graph-Pad 
Prism 6.0.
All supplementary materials are available 
online at www.molmed.org.
RESULtS
Clinical Characterization of  Children 
with interstitial Lung Disease and R288K
In our cohort of 228 children with ILD 
and ABCA3 sequenced, we identified 
11 subjects as carriers of R288K. This 
frequency of R288K was clearly enriched 
over that in the general Caucasian pop-
ulation (71 R288K in 4,229 Caucasian 
subjects of the Exom variant server 
(National Heart, Lung and Blood Insti-
tute Exome Variant Server) (P = 0.0014)). 
We next analyzed the dependency on 
gestational age of the different ABCA3 
variants identified. Whereas all the other 
possibly disease causing ABCA3 variants 
were evenly distributed among mature 
and immature infants, R288K was found 
more frequently in premature infants 
(Table 1).
All our patients carrying a single 
 heterozygous R288K variant were 
 Caucasians, had nonconsanguineous  
parents and did not carry known disease- 
causing genetic variants in SFTPC and 
SFTPB (Supplementary Table 1). In all 
protein or R288K variant were seeded as 
octuplicate in 96-well plates at a density 
of 1 × 105 cells per well. After attaching 
to the 96-well plate HEK293 cells were 
treated with different concentrations of 
doxorubicin for 3 h. Cells were washed 
subsequently with PBS and incubated for 
further 24 h in RPMI medium containing 
10 % FCS and no phenol red under nor-
mal conditions. Viability was  measured 
with XTT assay (as  previously described).
Electron Microscopy
Cells were fixed in 150 mmol/L 
HEPES, pH 7.35, containing 1.5 % 
formaldehyde and 1.5 % glutaralde-
hyde at room temperature for 30 min 
and then at 4°C overnight. After 
 dehydration in acetone, cells were 
 embedded in EPON. 50 nm sections 
were stained with 4 % uranyl acetate 
and lead citrate and observed in a Mor-
gagni TEM. Images were taken with a 
2 K side mounted Veleta CCD camera.
Calculation of Vesicle Volume
A549 cells containing either ABCA3 
wild type or R288K protein variant 
were seeded in eight-well slides. After 
an incubation time of 48 h, cells were 
fixed as described above and immu-
nostained against HA-tag. Cells were 
imaged with the confocal laser scan-
ning microscope. Diameter of each 
ABCA3-HA containing vesicle was 
 determined with ImageJ (NIH; http://
rsb.info.nih.gov/ij/) software tool. 




* * 3π . Sixty different 
ABCA3-HA containing vesicles were 
randomly chosen from three distinct 
experiments, thus analyzing 20 vesicles 
per condition and experiment.
Statistical analyses
Dependency on gestational age of the 
different ABCA3 variants was analyzed 
using Fisher exact test. Comparisons of 
two groups were done using Student 
t test. Comparisons of multiple groups 
were done using one-way repeated mea-
sure ANOVAs with Tukey post hoc test. 
Doxorubicin assay, phospholipid (PL) 
table 1. Frequencies of ABCA3 variants among 228 neonates and infants (mean gestational 
age 35.4 wks) sequenced for ABCA3 variants and interstitial lung disease.
Gestational age (wks) <37 ≥37
Mean gestational age (wks) 31.6 31.3 39.4 39.4
ABCA3 variant present Yes No Yes No Pa
Any variants 15 48 47 118 0.5106
R288K  6  8  5  43 0.0012
R288K without other disease  
causing ABCA3 variant (n = 2)
 6  8  3  43 0.0001 
aFisher exact test
R E S E A R C H  A R T I C L E
 M O L  M E D  2 2 : 1 8 3 - 1 9 1 ,  2 0 1 6  |  W i t t M a n n  E t  a L .  |  1 8 7
transcription of 200-fold compared with 
mock transfected cells (Supplementary 
Figure 1A). Intracellular processing as 
assessed by Western immunoblotting 
did not differ between ABCA3-WT and 
ABCA3-R288K. Both proteins were present 
transcription, intracellular Processing, 
and Cellular targeting of R288K in 
aBCa3-transfected Lung Cells
Stable transfection of A549 cells 
with DNA coding for ABCA3-WT or 
ABCA3-R288K induced ABCA3-mRNA 
healthy  children (Figure 1). In three other 
 subjects, no such investigations were 
done due to mild and improving course.
It was of interest that all patients het-
erozygous for R288K presented to us as 
 infants or children, rather than as neonates, 
with an unusual course of ILD, and which 
their treating  physicians could not explain 
by prematurity or perinatal lung injury. All 
surviving  children improved, but their ILD 
was not cured at follow up. Despite broad 
clinical  investigations, no other causes of 
their ILD could be identified.
To summarize, these children with 
chronic ILD had enrichment of the R288K 
variant in ABCA3 and somewhat  reduced 
dipalmitoyl-phosphatidylcholine in the  
alveolar space, that is, strong epidemi-
ologic and biochemical evidence for an 
involvement of ABCA3 in their patho-
genesis. Although the R288K  variant 
was predicted not to be detrimental to 
protein function by SIFT and Polyphen, 
our data nonetheless suggest impairment 
of ABCA3 function due to the presence 
of this particular variant. Therefore, we 
performed detailed studies on the cellular 
effects of the R288K variant.
table 2. Ex vivo evidence for functionality of ABCA3 transport activity.
Patient Codea
Immunohistologic 
staining for ABCA3 Electron microscopy
Dipalmitoyl-
phosphatidylcholine  
(PC 32:0) (% total PC)  
in BAL
Overall evidence 




Type 2 cells with  
granular ring-like  
structures Concentric lamellar 45.8 ± 3.6b
1 199 NA Yes, normal 40.8 Yes
2 652 NA NA 40.7 Yes
3 1300 Yes, normal Yes, normal 41.1 Yes
4 1468 Yes, normal NA 42.1c Yes
5 1479 Yes, normal NA 23.5 Yes, marginal
6 1601 NA NA NA Yes, no investigations 
as mild course
7 2253 Yes, normal Yes, normal 30.6c Yes
8 2405 NA NA NA Yes, no investigations 
as mild course
9 2741 NA NA NA Yes, no investigations as 
mild course
NA, not available
aGriese, Kiermeier et al. 2015.
bDipalmitoyl-phosphatidylcholine (PC 32:0) was 12.7 ± 4.2 % of total PC in four subjects with severe neonatal disease causing ABCA3 variants.
cLung tissue.
Figure 1. Levels of phosphatidylcholine and dipalmitoyl-phosphatidylcholine in 
 bronchoalveolar lavage fluid of infants heterozygous for R288K in ABCA3. (A) Phosphati-
dylcholine of patients carrying heterozygote R288K variant (n = 4) compared with healthy 
control group (n = 11). Data are shown in % of all analyzed PL classes measured in BAL. 
(B) Dipalmitoyl-phosphatidylcholine amounts of healthy patients (n = 11) and  patients with 
R288K variant (n = 4) measured in BAL. Data are shown in % of total PC. All results were 
 expressed as mean ± SEM. *P < 0.05; ***P < 0.001.
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cells stably expressing ABCA3-R288K, 
smaller ABCA3-positive vesicles were 
found compared with cells expressing 
ABCA3-WT protein (Figure 4).
DiSCUSSiOn
In this study we present a cohort of 
children with chronic ILD character-
ized by their carriage of a single R288K 
variant of ABCA3. All children suffered 
from a mainly restrictive lung disease 
or R288K mutated protein revealed an 
induction of lamellar body (LB)-like  
structures in A549 cells (Figures 3A, B).  
LB-like structures of both cell lines 
showed well-formed organelles contain-
ing concentric membranes arranged in 
parallel. Volumes of LB-like structures 
in cells expressing ABCA3-R288K were 
quantitatively compared with cells ex-
pressing ABCA3-WT protein. Using 
immunofluorescence staining of A549 
as the 190 and 170 kDa processing forms 
( Supplementary Figure 1B) and their inten-
sity ratios did not differ ( Supplementary 
Figure 1C). Cell growth and  proliferation 
were unaffected in comparison to mock 
controls ( Supplementary Figure 1D, E). 
Intracellular localization was investigated 
by immunofluorescence staining and re-
vealed normal colocalization of both the 
wild type and the R288K mutated ABCA3 
protein with CD63, a marker for late endo-
somes and lamellar bodies ( Supplementary 
Figure 1F). Obvious protein misfolding 
was ruled out by lack of colocalization 
with the ER-resident chaperone calnexin 
( Supplementary  Figure 1G). These find-
ings were confirmed independently in 
HEK293 cells. Whereas there was no 
difference in protein expression, mRNA 
expression differed between ABCA3-WT 
and ABCA3-R288K expressing cells 
 (Supplementary Figure 2).
impaired aBCa3-Dependent 
 Doxorubicin Detoxification  
in R288K Variants
ABCA3 transport activity was  
analyzed in HEK293 cells  stably trans-
fected with ABCA3-WT or ABCA3-R288K 
by means of their ability to detoxify 
doxorubicin (Figure 2). High activity of 
the transporter, that is, overexpression 
of ABCA3 protein in childhood acute 
myeloic leukemia patients, induced 
resistance against doxorubicin (23). 
HEK293 cells stably expressing R288K 
mutated ABCA3 protein had a dimin-
ished viability compared with cells 
expressing WT protein when treated 
with 5, 10 or 20 μmol/L of doxorubicin 
respectively (Figure 2A). In concordance, 
the morphology of the cells expressing 
ABCA3-R288K was altered to a round-
shaped appearance compared with  
ABCA3-WT expressing cells (Figure 2B; 
10 μmol/L doxorubicin). These results 
point to a reduced ABCA3 transport  
activity as a result of the R288K variant.
Lamellar Bodies of aBCa3 with the 
R288K Variant
Electron microscopy of A549 cells  
stably expressing ABCA3-WT  
Figure 3. Transmission electron microscopy. Electron microscopy of A549 cells expressing 
ABCA3-WT (A) or ABCA3-R288K (B). Several lamellar bodies are visible in the overviews. 
These exhibit concentric lamellae, as distinguishable in the higher magnifications (insets). 
Scale bars are 1 μm for overviews and 0.5 μm for insets.
Figure 2. Induction of cellular multidrug resistance in vitro by ABCA3. (A) Effects of soluble 
doxorubicin on viability of HEK293 cells stably expressing ABCA3-WT or ABCA3-R288K protein. 
Different concentrations of doxorubicin were used and viability was measured with XTT assay. 
Values are displayed as means ± SEM of HEK293 cells stably expressing either ABCA3 wild-type 
protein (solid line) or R288K  mutated ABCA3 protein (dashed line). *P < 0.05; ****P < 0.0001. 
(B) Light microscopy of HEK293 cells stably expressing ABCA3-WT and  ABCA3-R288K protein 
respectively. Additionally cells were treated with 10 μmol/L doxorubicin for 3 h and displayed 
after 24 h of growth in RPMI medium supplemented with 10% FCS under normal conditions.
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infancy (CPI), interstitial emphysema, 
 dystelectasis and eosinophilia, often in 
combination. Such  heterogeneity is not 
unusual, even in the presence of the 
same disease causing variants (2,4,21), 
and likely represents the morphologic 
response of lung parenchyma to variable 
injuries in different individuals.
Our data suggest that heterozygous 
R288K variants in ABCA3 are not strong 
enough determinants permitting the 
manifestation of ILD in the absence of 
additional factors. This is supported by 
the fact that only two out of nine parents 
carrying the variant had some, but not 
severe, respiratory symptoms. However, 
the precise nature of their conditions was 
not investigated to great detail. In our 
patients, neonatal respiratory distress 
was a consistent feature, together with 
injury from recurrent airway infections. 
The strong interaction of single ABCA3 
variants and prematurity was previously 
demonstrated (17) and confirmed here. 
Other modifying factors may be pres-
ent like cis-acting elements, introns or 
nontranslated regions within the ABCA3 
gene, which were not covered by our se-
quencing strategy (24). Whereas variants 
in SFTPC or SFTPB were excluded, vari-
ants in other genes not directly related to 
ABCA3 expression, epigenetic regulation 
and additional environmental or devel-
opmental factors are also conceivable. 
Furthermore, previous studies showed 
that some ABCA3 variants had a mild 
cellular effect, associated with increased 
inflammation (25).
Lower levels of phosphatidylcholine 
and dipalmitoyl-phosphatidylcholine in 
the alveolar space of the infants are likely 
to be a result of functional  impairment 
of ABCA3-R288K. The other phospho-
lipid species (lyso- phosphatidylcholine, 
phosphatidylglycerol,  sphingomyelin, 
phosphatidylethanolamine, 
 phosphatidylserine) were not differ-
ent. Additionally, a reduced capacity 
for  detoxification of doxorubicin and a 
smaller volume of ABCA3-positive vesi-
cles provide in vitro evidence for reduced 
ABCA3 transport function due to the 
presence of the R288K variant. Taken 
frequently leading to early death (11,12) 
or chronic ILD in a small number of older 
children and young adults (14,15). In this 
study, we characterize subjects carrying 
the R288K variant on a single allele and 
suffering from a characteristic chronic 
pediatric ILD phenotype. Whereas the 
individual course of their lung disease 
was quite variable, all  patients had a 
characteristic diffuse  parenchymal lung 
disease. Histology of lung biopsies 
demonstrated ILD  present with almost 
the entire spectrum of  histologic patterns 
known for these conditions, including 
pulmonary  alveolar proteinosis (PAP), 
nonspecific interstitial pneumonitis 
(NSIP),  desquamative interstitial pneu-
monitis (DIP), chronic pneumonitis of 
with the typical histological and chest 
CT imaging pattern of chronic pediatric 
ILD.  However, they did not exhibit the 
generic features of complete ABCA3 
deficiency. We present evidence that 
the presence of the R288K variant inter-
feres with ABCA3′s transport activity. 
Therefore, we propose that the devel-
opment and long-term persistence of 
chronic ILD in our cohort was due to 
the presence of a single R288K variant 
of ABCA3 and not a result of their 
 neonatal history of respiratory distress 
following either term or preterm birth.
Manifestation of ABCA3 deficiency 
due to homozygous or compound 
 heterozygous variants causes severe 
 respiratory distress in mature infants, 
Figure 4. Determination of vesicle volumes in A549 cells with ABCA3-WT or ABCA3-R288K 
protein. (A) Immunofluorescence staining of HA-tagged ABCA3 vesicles imaged with 
a confocal microscope. Shown is either ABCA3-WT (left) or ABCA3-R288K containing 
vesicles (right). (B) Volumes of ABCA3 containing vesicles harboring either ABCA3-WT or 
ABCA3-R288K were calculated on the basis of vesicle diameters determined with ImageJ 
software tool. ***P < 0.001.
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generation sequencing data need to be 
backed by clinical and experimental data.
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other hand, this is a third and indepen-
dent cohort demonstrating some patho-
genic potential of R288K, showing for the 
first time a role in pediatric ILD, and pro-
viding detailed cell biological analysis.
Taken together, we show that the pres-
ence of the ABCA3-R288K variant on a 
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